Serine protease inhibitor Kazal type 1(SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To investigate serine protease inhibitor Kazal type 1(SPINK1) expression and its influence on the prognosis of human hepatocellular carcinoma(HCC) and to explore the underlying molecular mechanisms involved.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Dig Dis

Title: Journal of digestive diseases

Publisher: Wiley-Blackwell

ISSN (Electronic): 1751-2980

ISSN (Print): 1751-2972

Publication date (Electronic): May 23 2017

Affiliations

[1 ] Department of Geriatrics, Shanghai General Hospital of Nanjing Medical University, Shanghai, China, 200080.

[2 ] Department of Gastroenterology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China, 200080.

Article

DOI: 10.1111/1751-2980.12486

PubMed ID: 28544403

SO-VID: 2efb5bd6-1cfa-4446-882b-adde2f37f98b

History

Keywords: MEK/ERK signaling pathway,SPINK1,endothelial-mesenchymal transition,hepatocellular carcinoma

Data availability:

Keywords: MEK/ERK signaling pathway, SPINK1, endothelial-mesenchymal transition, hepatocellular carcinoma

Serine protease inhibitor Kazal type 1(SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.

Read this article at

Abstract

Related collections

Universal stem cells

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 15